Published in Biotech Law Weekly, October 1st, 2004
The compounds work by preventing proteins, known as classical cadherins, from properly acting as the "biological glues" that hold tumor cells together. Cancer cells die through a process known as apoptosis when cell-to-cell binding is inhibited.
"This patent is important to Adherex as it focuses specifically on the core...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.